Dr. Max Kates, MD
Claim this profileJohn Hopkins University
Studies Skin Cancer
Studies Transitional Cell Carcinoma
2 reported clinical trials
3 drugs studied
Area of expertise
1Skin Cancer
Stage II
Stage I
2Transitional Cell Carcinoma
Stage II
Stage I
Affiliated Hospitals
More about Max Kates, MD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 0 Active Clinical TrialsTreatments Max Kates, MD has experience with
- Docetaxel
- Gemcitabine
- UGN-102
Breakdown of trials Max Kates, MD has run
Transitional Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Max Kates, MD specialize in?
Max Kates, MD focuses on Skin Cancer and Transitional Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage II patients, or patients who are Stage I.
Is Max Kates, MD currently recruiting for clinical trials?
No, Max Kates, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Max Kates, MD has studied deeply?
Yes, Max Kates, MD has studied treatments such as Docetaxel, Gemcitabine, UGN-102.
What is the best way to schedule an appointment with Max Kates, MD?
Apply for one of the trials that Max Kates, MD is conducting.
What is the office address of Max Kates, MD?
The office of Max Kates, MD is located at: John Hopkins University, Baltimore, Maryland 21218 United States. This is the address for their practice at the John Hopkins University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.